The research agenda of the National Institute of Allergy and Infectious Diseases for antimicrobial resistance

Journal of Infectious Diseases

Volumn 197, Issue 8, 2008, Pages 1087-1093

  Peters, N Kent ^a   Dixon, Dennis M ^a   Holland, Steven M ^a   Fauci, Anthony S ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMISIN; AZITHROMYCIN; BENZATHINE PENICILLIN; CEFALEXIN; CHLOROQUINE; CLINDAMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; ISONIAZID; MACROLIDE; NITROIMIDAZOLE; RIFAMPICIN; TETRACYCLINE; TINIDAZOLE; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; BACTERIAL SURVIVAL; CLINICAL TRIAL; DRUG RESEARCH; GRAM NEGATIVE INFECTION; HEALTH CARE ORGANIZATION; HUMAN; MALARIA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTIDRUG RESISTANCE; PATHOGENESIS; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW; SKIN INFECTION; SOFT TISSUE INFECTION; SYPHILIS; TUBERCULOSIS; URETHRITIS;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, BACTERIAL; HUMANS; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (U.S.); PUBLIC HEALTH; RESEARCH SUPPORT AS TOPIC; UNITED STATES;

EID: 42549086795     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/533451     Document Type: Review

References (28)

1. Klevens RM, Morrison MA, Nadle J, et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 2007; 298:1763-71.
2. Cardo D, Horan T, Andrus M, et al. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004; 32:470-85.
3. Jambou R, Legrand E, Niang M, et al. Resistance of Plasmodium falciparum field isolates to in-vitro artemether and point mutations of the SERCA-type PfATPase6. Lancet 2005; 366:1960-3.
4. Zignol M, Hosseini MS, Wright A, et al. Global incidence of multidrug-resistant tuberculosis. J Infect Dis 2006; 194:479-85.
5. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs: worldwide, 2000-2004. MMWR Morb Mortal Wkly Rep 2006; 55:301-5.
6. Shah NS, Wright A, Bai GH, et al. Worldwide emergence of extensively drug-resistant tuberculosis. Emerg Infect Dis 2007; 13:380-7.
7. Gandhi NR, Moll A, Sturm AW, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006; 368:1575- 80.
8. Moll A. Treatment of HIV associated XDR TB patients [abstract]. In: Program or abstracts of the 38th Lung Health Conference (Cape Town). 2007.
9. D'Costa VM, McGrann KM, Hughes DW, Wright GD. Sampling the antibiotic resistome. Science 2006; 311:374-7.
10. Spellberg B, Powers JH, Brass EP, Miller LG, Edwards J, John E. Trends in antimicrobial drug development: implications for the future. Clin Infect Dis 2004; 38:1279-86.
11. Beg QK, Vazquez A, Ernst J, et al. Intracellular crowding defines the mode and sequence of substrate uptake by Escherichia coli and constrains its metabolic activity. Proc Natl Acad Sci USA 2007; 104:12663-8.
12. Levy SB. Active efflux, a common mechanism for biocide and antibiotic resistance. J Appl Microbiol 2002; 92(Suppl):65S-71S.
13. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science 1999; 284:1318-22.
14. Banin E, Brady KM, Greenberg EP. Chelator-induced dispersal and killing of Pseudomonas aeruginosa cells in a biofilm. Appl Environ Microbiol 2006; 72:2064-9.
15. Tang HM, Hamblin MR, Yow CM. A comparative in vitro photoinactivation study of clinical isolates of multidrug-resistant pathogens. J Infect Chemother 2007; 13:87-91.
16. Foley JW, Song X, Demidova TN, Jalil F, Hamblin MR. Synthesis and properties of benzo[a] phenoxazinium chalcogen analogues as novel broad-spectrum antimicrobial photosensitizers. J Med Chem 2006; 49:5291-9.
17. Voyich JM, Otto M, Mathema B, et al. Is Panton-Valentine leukocidin the major virulence determinant in community-associated methicillin-resistant Staphylococcus aureus disease? J Infect Dis 2006; 194:1761-70.
18. Labandeira-Rey M, Couzon F, Boisset S, et al. Staphylococcus aureus Panton-Valentine leukocidin causes necrotizing pneumonia. Science 2007; 315:1130-3.
19. Wang R, Braughton KR, Kretschmer D, et al. Identification of novel cytolytic peptides as key virulence determinants for community-associated MRSA. Nat Med 2007; 13:1510-4.
20. Network on Antimicrobial Resistance in Staphylococcus aureus. Available at: http://www.narsa.net/. Accessed 5 December 2007.
21. NIAID Microbial Sequencing Centers. Available at: http://www.niaid.nih. gov/dmid/genomes/mscs/. Accessed 25 February 2008.
22. Sarkar S, DeSantis ER, Kuper J. Resurgence of colistin use. Am J Health Syst Pharm 2007; 64:2462-6.
23. United States Department of Health and Human Services. The Jordan report: accelerated development of vaccines 2007. Publication 06-6057. Bethesda, MD: National Institutes of Health, 2007:157.
24. Schaffer AC, Solinga RM, Cocchiaro J, et al. Immunization with Staphylococcus aureus clumping factor B, a major determinant in nasal carriage, reduces nasal colonization in a murine model. Infect Immun 2006; 74:2145-53.
25. Stranger-Jones YK, Bae T, Schneewind O. Vaccine assembly from surface proteins of Staphylococcus aureus. Proc Natl Acad Sci USA 2006; 103:16942-7.
26. McKenney D, Pouliot KL, Wang Y, et al. Broadly protective vaccine for Staphylococcus aureus based on an in vivo-expressed antigen. Science 1999; 284:1523-7.
27. Interagency Task Force on Antimicrobial Resistance. Available at: http://www.cdc.gov/drugresistance/actionplan/index.htm. Accessed 5 December 2007.
28. Treating infectious diseases in the microbial world: report of two workshops on novel antimicrobial therapeutics. Washington, DC: National Academies Press, 2006. Available at: http://www.nap.edu/catalog/11471. html. Accessed 5 December 2007.